ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections.Journal of clinical pharmacology · 2026Trial
- Gepotidacin and Early Symptom Improvement in Uncomplicated Urinary Tract Infection: A Nonrandomized Clinical Trial.JAMA network open · 2026Trial
- Efficacy andAntimicrobial agents and chemotherapy · 2025Trial
- Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections.Open forum infectious diseases · 2025Trial
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Patterns of Antibiotic Utilization and Bacterial Susceptibility of Prenatal Urinary Tract Infections.Journal of women's health (2002) · 2026Article
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- Molecular and environmental drivers of antimicrobial resistance: global epidemiology, resistome dynamics, and one health strategies.Archives of microbiology · 2026Review
- Antimicrobial resistance surveillance of clinical bacterial isolates at Maryamana private hospital, Erbil-Iraq (2023-2025): antibiogram data and multidrug-resistant (MDR)/extensively drug-resistant (XDR)/pandrug-resistant (PDR) classification.Iranian journal of microbiology · 2026Article
- Microbiological findings, antibiotic resistance rates and prescription practices for older women with recurrent urinary tract infections: a descriptive study alongside a multinational randomized controlled trial (ImpresU).JAC-antimicrobial resistance · 2026Article
- Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.Open forum infectious diseases · 2026Article
- Comprehensive Evaluation of Uropathogens' AMR in a Romanian Tertiary Center: Male vs. Female Comparison.Microorganisms · 2026Article
- Antibiofilm Potential and Mechanisms ofMicroorganisms · 2026Article
- Article
- Molecular characterization of virulence and multidrug resistance inVeterinary world · 2026Article
- Bladder p75Life (Basel, Switzerland) · 2025Article
- Article
- Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set ofAntimicrobial agents and chemotherapy · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUncomplicated urinary tract infection (uUTI) is predominantly caused by Escherichia coli, which has increasing antimicrobial resistance (AMR) at the United States (US)-community level. As uUTI is often treated empirically, assessing AMR is challenging, and there are limited contemporary data characterizing period prevalence in the US.
methodsThis was a retrospective study of AMR using Becton, Dickinson and Company Insights Research Database (Franklin Lakes, New Jersey, US) data collected 2011-2019. Thirty-day, nonduplicate Escherichia coli urine isolates from US female outpatients (aged ≥12 years) were included. Isolates were evaluated for nonsusceptibility (intermediate/resistant) to trimethoprim-sulfamethoxazole, fluoroquinolones, or nitrofurantoin, and assessed for extended-spectrum β-lactamase production (ESBL+) and for ≥2 or ≥3 drug-resistance phenotypes. Generalized estimating equations were used to model AMR trends over time and by US census region.
resultsAmong 1 513 882 E. coli isolates, the overall prevalence of isolates nonsusceptible to trimethoprim-sulfamethoxazole, fluoroquinolones, and nitrofurantoin was 25.4%, 21.1%, and 3.8%, respectively. Among the isolates, 6.4% were ESBL+, 14.4% had ≥2 drug-resistance phenotypes, and 3.8% had ≥3. Modeling demonstrated a relative average yearly increase of 7.7% (95% confidence interval [CI], 7.2-8.2%) for ESBL+ isolates and 2.7% (95% CI, 2.2-3.2%) for ≥3 drug-phenotypes (both P < .0001). Modeling also demonstrated significant variation in AMR prevalence between US census regions (P < .001).
conclusionsPeriod prevalence of AMR among US outpatient urine-isolated E. coli was high, and for multidrug-resistance phenotypes increased during the study period with significant variation between census regions. Knowledge of regional AMR rates helps inform empiric treatment of community-onset uUTI and highlights the AMR burden to physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.